

2023 SPECIALTY DRUGS PRIOR AUTHORIZATION LIST FOR ADMINISTRATIVE SERVICES ONLY MEMBERS

Updated December 2023 to reference changes through April 2024

EXCEPT AS OTHERWISE NOTED IN THE UPDATE HISTORY COLUMN, THESE PRIOR AUTHORIZATION REQUIREMENTS ARE EFFECTIVE ON SEPTEMBER 18, 2023

PRESS "CTRL" AND "F" KEYS AT THE SAME TIME TO BRING UP THE SEARCH BOX. ENTER A PROCEDURE CODE OR DRUG NAME.

For Medical Policy information, please access the BCBSNM Medical Policy Website

Carelon Medical Benefits Management = Med Oncology & Supportive Care

Blue Cross Blue Shield of New Mexico (BCBSNM) = Provider Administered Therapy Or Infusion Site Of Care

Send PA requests to BCBSNM for Provider Administered Therapy or Infusion Site of Care.

Send PA requests to Carelon for Medical Oncology and Supportive care unless drug requested has multiple indications. Carelon will only review requests for oncology drugs that are supported by an oncology diagnosis. Refer to the Update History / Prior Authorization Delegation Notes for details.

| Procedure Code | Category | Drug Product Name* Brand (generic) *Trademarks are the property of their respective owners. 🛙 | Managed By | Update History / Delegation Notes*** (Highlighted = Multiple Indications) ***Some drugs / codes on this PA list have multiple indications. Carelon will only review requests that are supported by an oncology diagnosis. See details provided on this list for each drug/code. |
|----------------|---------------------------------------|--|------------|--|
| C9163 | Medical Oncology & Supportive Care | Talvey (talquetamab-tgvs) | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| C9165 | Medical Oncology & Supportive Care | Elrexfio (elranatamab-bcmm) | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| J1576 | Medical Oncology & Supportive Care | Panzyga (immune globulin intravenous, human-ifas) | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| J9064 | Medical Oncology & Supportive Care | Cabazitaxel (sandoz) | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| J9259 | Medical Oncology & Supportive Care | Paclitaxel protein-bound particles (american regent) | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| J9286 | Medical Oncology & Supportive Care | Columvi (glofitamab-gxbm) | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |

| J9321 | Medical Oncology & Supportive Care | Epkinly (epcoritamab-bysp) | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
|-------|--|--------------------------------|---------|---|
| Q2049 | Medical Oncology & Supportive Care | Imported Lipodox Inj | Carelon | Retire Effective 04/01/2024. |
| J1726 | Provider Administered Drug Therapy | Makena 10 Mg | BCBSNM | Retire effective 01/01/2024 |
| C9094 | Infusion Site of Care | Inj Sutimlimab-Jome 10 Mg | BCBSNM | Code Termed 10/01/2022 - This code is replaced with J1302 |
| J0129 | Infusion Site of Care | Abatacept Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J0180 | Infusion Site of Care | Agalsidase Beta Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J0219 | Infusion Site of Care | Inj Aval Alfa-Nqpt 4Mg | BCBSNM | Add effective 04/01/2023 |
| J0221 | Infusion Site of Care | Lumizyme (Alglucosidase Alfa) | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J0222 | Infusion Site of Care | Inj. Patisiran 0.1 Mg | BCBSNM | Prior Authorization required through BCBS. Add to Large Groups 10/01/2023. |
| J0223 | Infusion Site of Care | Inj Givosiran 0.5 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0224 | Infusion Site of Care | Inj. Lumasiran 0.5 Mg | BCBSNM | Add effective 04/01/2023 |
| J0490 | Infusion Site of Care | Benlysta (Belimumab) | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J0491 | Infusion Site of Care | Inj Anifrolumab-Fnia 1Mg | BCBSNM | Add effective 04/01/2023 |
| J0517 | Infusion Site of Care | Inj. Benralizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0584 | Infusion Site of Care | Injection Burosumab-Twza 1M | BCBSNM | Prior Authorization required through BCBS. Add to Large Groups 10/01/2023. |
| J0598 | Infusion Site of Care | C-1 Esterase Cinryze | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J0638 | Infusion Site of Care | Canakinumab Injection | BCBSNM | Prior Authorization required through BCBS. |
| J0717 | Infusion Site of Care | Certolizumab Pegol Inj 1Mg | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |

| J0791 | Infusion Site of Care | Inj Crizanlizumab-Tmca 5Mg | BCBSNM | Prior Authorization required through BCBS. |
|-------|-----------------------|------------------------------|--------|---|
| J1290 | Infusion Site of Care | Ecallantide Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1300 | Infusion Site of Care | Eculizumab Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1301 | Infusion Site of Care | Injection Edaravone 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1302 | Infusion Site of Care | Inj Sutimlimab-Jome 10 Mg | BCBSNM | Add Effective 07/01/2023 |
| J1303 | Infusion Site of Care | Inj. Ravulizumab-Cwvz 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1305 | Infusion Site of Care | Inj Evinacumab-Dgnb 5Mg | BCBSNM | Add effective 04/01/2023 |
| J1306 | Infusion Site of Care | Injection Inclisiran 1 Mg | BCBSNM | Add effective 04/01/2023 |
| J1322 | Infusion Site of Care | Elosulfase Alfa Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1458 | Infusion Site of Care | Galsulfase Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1602 | Infusion Site of Care | Golimumab For Iv Use 1Mg | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1743 | Infusion Site of Care | Idursulfase Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1745 | Infusion Site of Care | Infliximab Not Biosimil 10Mg | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1746 | Infusion Site of Care | Inj. Ibalizumab-Uiyk 10 Mg | BCBSNM | Prior Authorization required through BCBS. Add to Large Groups 10/01/2023. |
| J1786 | Infusion Site of Care | Imuglucerase Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1823 | Infusion Site of Care | Inj. Inebilizumab-Cdon 1 Mg | BCBSNM | Add effective 04/01/2023 |
| J1931 | Infusion Site of Care | Laronidase Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J2182 | Infusion Site of Care | Injection Mepolizumab 1Mg | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |

| J2323 | Infusion Site of Care | Natalizumab Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
|-------|-----------------------|---------------------------------|--------|---|
| J2350 | Infusion Site of Care | Injection Ocrelizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J2356 | Infusion Site of Care | Inj Tezepelumab-Ekko 1Mg | BCBSNM | Add effective 04/01/2023 |
| J2357 | Infusion Site of Care | Omalizumab Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J2507 | Infusion Site of Care | Krystexxa (Pegloticase) | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J2786 | Infusion Site of Care | Injection Reslizumab 1Mg | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J2840 | Infusion Site of Care | Inj Sebelipase Alfa 1 Mg | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J3032 | Infusion Site of Care | Inj. Eptinezumab-Jjmr 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J3060 | Infusion Site of Care | Inj Taliglucerace Alfa 10 U | BCBSNM | Prior Authorization required through BCBS. |
| J3241 | Infusion Site of Care | Inj. Teprotumumab-Trbw 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J3245 | Infusion Site of Care | Inj. Tildrakizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. Add to Large Groups 10/01/2023. |
| J3262 | Infusion Site of Care | Tocilizumab Injection | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J3358 | Infusion Site of Care | Ustekinumab Iv Inject 1 Mg | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J3380 | Infusion Site of Care | Injection Vedolizumab | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J3385 | Infusion Site of Care | Velaglucerase Alfa | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J3397 | Infusion Site of Care | Inj. Vestronidase Alfa-Vjbk | BCBSNM | Prior Authorization required through BCBS. Add to Large Groups 10/01/2023. |
| J9332 | Infusion Site of Care | Inj Efgartigimod 2Mg | BCBSNM | Add effective 04/01/2023 |

| Q5103 | Infusion Site of Care | Injection Inflectra | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
|-------|---|----------------------------|----------------------|--|
| Q5104 | Infusion Site of Care | Injection Renflexis | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| Q5109 | Infusion Site of Care | Injection Ixifi 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| Q5121 | Infusion Site of Care | Inj. Avsola 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1459 | Infusion Site of Care, Medical Oncology & Supportive Care | Inj Ivig Privigen 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1551 | Infusion Site of Care, Medical Oncology & Supportive Care | Inj Cutaquig 100 Mg | Carelon or BCBSNM | Add Effective to SOC 4/1/2023; Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1554 | Infusion Site of Care, Medical Oncology & Supportive Care | Inj. Asceniv | Carelon or BCBSNM | Add Effective 4/1/2023; Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1555 | Infusion Site of Care, Medical Oncology & Supportive Care | Inj Cuvitru 100 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1556 | Infusion Site of Care, Medical Oncology & Supportive Care | Inj Imm Glob Bivigam 500Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |

| J1557 J1558 | Medical Oncology & Supportive Care Infusion Site of Care, Medical Oncology & | (Gammaplex_(Injection, Immune Globulin, , Intravenous, Nonlyophilized (E.G., Liquid), 500 Mg) Inj. Xembify 100 Mg | Carelon or BCBSNM Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. Carelon will review requests for oncology drugs that are supported by |
|----------------|---|---|--|--|
| | Supportive Care | | | an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1559 | Infusion Site of Care, Medical Oncology & Supportive Care | Hizentra Injection | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1561 | Infusion Site of Care, Medical Oncology & Supportive Care | Gamunex-C/Gammaked | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1566 | Infusion Site of Care, Medical Oncology & Supportive Care | Injection, Immune Globulin, Intravenous, Lyophilized (E.G., Powder), Not Otherwise Specified, 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1568 | Infusion Site of Care, Medical Oncology & Supportive Care | Octagam Injection | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |

| J1569 | Infusion Site of Care, Medical Oncology & Supportive Care | Gammagard Liquid Injection | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an |
|-------|---|---|----------------------|--|
| | | | | oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1572 | Infusion Site of Care, Medical Oncology & Supportive Care | Flebogamma Injection | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J1575 | Infusion Site of Care, Medical Oncology & Supportive Care | Hyqvia 100Mg Immuneglobulin | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| C9142 | Medical Oncology & Supportive Care | Alymsys (Bevacizumab-Maly) | Carelon | Add effective 01/01/2023 though will be removed and replaced with Q5126 04/01/2023, Prior Authorization required through Carelon. |
| C9146 | Medical Oncology & Supportive Care | Elahere (Mirvetuximab Soravtansine-Gynx) | Carelon | Code Termed 07/01/2023 - This code is replaced with J9063 |
| C9147 | Medical Oncology & Supportive Care | Imjudo (Tremelimumab-Actl) | Carelon | Code Termed 07/01/2023 - This code is replaced with J9347 |
| C9148 | Medical Oncology & Supportive Care | Tecvayli (Teclistamab-Cqyv) | Carelon | Code Termed 07/01/2023 - This code is replaced with J9380 |
| C9399 | Medical Oncology & Supportive Care | Unituxin (Dinutuximab) | Carelon | Code represents unclassified drugs or biologics. Effective 01/01/2023, add new drug Unituxin (dinutuximab) and Alymsys (bevacizumab-maly); Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J0641 | Medical Oncology & Supportive Care | Inj Levoleucovorin Nos 0.5Mg | Carelon | Prior Authorization required through Carelon. |
| J0642 | Medical Oncology & Supportive Care | Injection Khapzory 0.5 Mg | Carelon | Prior Authorization required through Carelon. |

| J0882 | Medical Oncology & Supportive Care | Darbepoetin Alfa Esrd Use | Carelon | Prior Authorization required through Carelon. |
|-------|------------------------------------|---|---------|---|
| J0896 | Medical Oncology & | Inj Luspatercept-Aamt 0.25Mg | Carelon | Prior Authorization required through |
| | Supportive Care | , | | Carelon. |
| J0897 | | Injection, Denosumab, 1 Mg, | Carelon | Prior Authorization required through |
| | | Prolia/Xgeva_(Denosumab) | | Carelon. |
| J1442 | Medical Oncology & | Inj Filgrastim Excl Biosimil | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J1447 | Medical Oncology & | Inj Tbo Filgrastim 1 Microg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J1448 | | Injection Trilaciclib 1Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J1449 | Medical Oncology & | Inj Eflapegrastim-Xnst 0.1Mg | Carelon | Add Effective 7/1/2023; Prior |
| | Supportive Care | | | Authorization required through |
| | | | | Carelon. |
| J2506 | Medical Oncology & | Inj Pegfilgrast Ex Bio 0.5Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J2820 | Medical Oncology & | Sargramostim Injection | Carelon | Prior Authorization required through |
| | Supportive Care | <i>.</i> , | | Carelon. |
| J2860 | Medical Oncology & | Injection Siltuximab | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J3490 | Medical Oncology & | Unituxin (Dinutuximab) | Carelon | Code represents unclassified drugs or |
| | Supportive Care | | | biologics. Effective 01/01/2023, add |
| | | | | new drug Unituxin (dinutuximab) and |
| | | | | Alymsys (bevacizumab-maly); Prior |
| | | | | Authorization required through |
| | | | | Carelon. |
| J3590 | Medical Oncology & | Unituxin (Dinutuximab) | Carelon | Code represents unclassified drugs or |
| | Supportive Care | | | biologics. Effective 01/01/2023, add |
| | | | | new drug Unituxin (dinutuximab) and |
| | | | | Alymsys (bevacizumab-maly); Prior |
| | | | | Authorization required through |
| | | | | Carelon. |
| J9019 | Medical Oncology & | Erwinaze Injection | Carelon | Add effective 01/01/2023. Prior |
| | Supportive Care | - | | Authorization required through |
| | | | | Carelon. |
| J9021 | Medical Oncology & | Inj Aspara Rylaze 0.1 Mg | Carelon | Add effective 01/01/2023. Prior |
| | Supportive Care | · · · · | | Authorization required through |
| | | | | Carelon. |
| J9022 | Medical Oncology & | Inj Atezolizumab 10 Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9023 | Medical Oncology & | Injection Avelumab 10 Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | 1 | Carelon. |

| J9032 | Medical Oncology & II | njection Belinostat 10Mg | Carelon | Effective 01/01/2023, Prior |
|--------|---|-----------------------------------|---------|--|
| | Supportive Care | | | Authorization move from BCBS to |
| | | | | Carelon. |
| J9037 | Medical Oncology & II | nj Belantamab Mafodont Blmf | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9039 | | njection Blinatumomab | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9042 | | Brentuximab Vedotin Inj | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9043 | с, С | evtana_(Cabazitaxel) | Carelon | Prior Authorization required through |
| 100.47 | Supportive Care | | Caralan | Carelon. |
| J9047 | | njection Carfilzomib 1 Mg | Carelon | Prior Authorization required through |
| J9055 | Supportive Care Medical Oncology & C | Cotuvinab Injection | Carelon | Carelon. Prior Authorization required through |
| 19022 | Supportive Care | Cetuximab Injection | Careion | Carelon. |
| J9057 | | nj. Copanlisib 1 Mg | Carelon | Prior Authorization required through |
| 19097 | Supportive Care | | carcion | Carelon. |
| J9061 | | nj Amivantamab-Vmjw | Carelon | Prior Authorization required through |
| | Supportive Care | , , | | Carelon. |
| J9063 | | nj Elahere 1 Mg | Carelon | Add Effective 7/1/2023; Prior |
| | Supportive Care | | | Authorization required through |
| | | | | Carelon. |
| J9118 | Medical Oncology & II | nj. Calaspargase Pegol-Mknl | Carelon | Add effective 01/01/2023; Prior |
| | Supportive Care | | | Authorization required through |
| | | | | Carelon. |
| J9119 | | nj. Cemiplimab-Rwlc 1 Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9144 | | Daratumumab Hyaluronidase | Carelon | Prior Authorization required through |
| 104.45 | Supportive Care | | | Carelon. |
| J9145 | | njection Daratumumab 10 | Carelon | Prior Authorization required through |
| J9153 | | vig nj Daunorubicin Cytarabine | Carelon | Effective 01/01/2023, Prior |
| 19122 | Supportive Care | | Careion | Authorization move from BCBS to |
| | Supportive care | | | Carelon. Prior Authorization required |
| | | | | through Carelon. |
| J9173 | Medical Oncology & II | nj. Durvalumab 10 Mg | Carelon | Prior Authorization required through |
| | Supportive Care | , | | Carelon. |
| J9176 | | njection Elotuzumab 1Mg | Carelon | Prior Authorization required through |
| | Supportive Care | - | | Carelon. |
| J9177 | Medical Oncology & II | nj Enfort Vedo-Ejfv 0.25Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9179 | Medical Oncology & F | Halaven_(Eribulin) | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9203 | | Gemtuzumab Ozogamicin 0.1 | Carelon | Prior Authorization required through |
| | | Иg | | Carelon. |
| J9204 | •. | nj Mogamulizumab-Kpkc 1 | Carelon | Prior Authorization required through |
| | Supportive Care N | Иg | | Carelon. |

| Supportive Care Medical Oncology & Ixa | | | Carelon. |
|---|--|---|--|
| | abepilone Injection | Carelon | Prior Authorization required through |
| | ij. Lurbinectedin 0.1 Mg | Carelon | Carelon. Prior Authorization required through |
| | | | Carelon. |
| | j. Isatuximab-Irfc 10 Mg | Carelon | Prior Authorization required through |
| | | | Carelon. |
| 0, | ervoy_(Ipilimumab) | Carelon | Prior Authorization required through |
| | | | Carelon. |
| | j Inotuzumab Ozogam 0.1 | Carelon | Prior Authorization required through |
| | 5 | | Carelon. |
| | aclitaxel Protein Bound | Carelon | Prior Authorization required through |
| | | | Carelon. |
| Medical Oncology & Pe | egaspargase Injection | Carelon | Add effective 01/01/2023. Prior |
| Supportive Care | | | Authorization required through |
| | | | Carelon. |
| Medical Oncology & In | j. Tagraxofusp-Erzs 10 Mcg | Carelon | Prior Authorization required through |
| Supportive Care | | | Carelon. |
| Medical Oncology & In | j Pembrolizumab | Carelon | Prior Authorization required through |
| Supportive Care | | | Carelon. |
| Medical Oncology & In | j Dostarlimab-Gxly 10 Mg | Carelon | Prior Authorization required through |
| Supportive Care | | | Carelon. |
| Medical Oncology & In | j Tisotu Vedotin-Tftv 1Mg | Carelon | Prior Authorization required through |
| Supportive Care | | | Carelon. |
| Medical Oncology & In | j Tebentafusp-Tebn 1 Mcg | Carelon | Add code effective 01/01/2023 for |
| Supportive Care | | | drug Kimmtrak (tebentafusp-tebn) |
| Medical Oncology & M | litomycin Instillation | Carelon | Prior Authorization required through |
| Supportive Care | | | Carelon. |
| Medical Oncology & In | jection Necitumumab 1 Mg | Carelon | Effective 01/01/2023, Prior |
| Supportive Care | | | Authorization move from BCBS to |
| | | | Carelon. Prior Authorization required |
| | | | through Carelon. |
| Medical Oncology & In | j Nivol Relatlimab 3Mg/1Mg | Carelon | Add effective 01/01/2023. Prior |
| Supportive Care | | | Authorization required through |
| | | | Carelon. |
| Medical Oncology & In | iection Nivolumab | Carelon | Prior Authorization required through |
| e, . | , | | Carelon. |
| | binutuzumab Ini | Carelon | Prior Authorization required through |
| 0, | | | Carelon. |
| | fatumumab Injection | Carelon | Prior Authorization required through |
| •. | | | Carelon. |
| | anitumumah Injection | Carelon | Prior Authorization required through |
| | | | Carelon. |
| | jection Parturumah 1 Ma | Carelon | Prior Authorization required through |
| Supportive Care | Jection Fertuzunian I Mg | | Carelon. |
| | Supportive CareMedical Oncology & Supportive CareMedical Oncology & In Supportive CareMedical Oncology & Supportive CareMedical Oncology & Supportive CareMedical Oncology & Supportive CareMedical Oncology & | Medical Oncology & Supportive CareInj. Isatuximab-Irfc 10 MgSupportive CareYervoy_(Ipilimumab)Supportive CareMgMedical Oncology & Supportive CarePaclitaxel Protein BoundMedical Oncology & Supportive CarePegaspargase InjectionMedical Oncology & Supportive CareInj. Tagraxofusp-Erzs 10 McgMedical Oncology & Supportive CareInj PembrolizumabMedical Oncology & Supportive CareInj Dostarlimab-Gxly 10 MgMedical Oncology & Supportive CareInj Tisotu Vedotin-Tftv 1MgSupportive CareInj Tebentafusp-Tebn 1 McgMedical Oncology & Supportive CareInj Tebentafusp-Tebn 1 McgMedical Oncology & Supportive CareInj pertive CareMedical Oncology & Supportive CareInj Tebentafusp-Tebn 1 McgSupportive CareMedical Oncology & Supportive CareMedical Oncology & Supportive CareInjection Necitumumab 1 MgSupportive CareInjection Nivolumab 1 MgSupportive CareInjection Nivolumab 1 MgSupportive CareInjection Nivolumab 1 MgSupportive CareObinutuzumab InjMedical Oncology & Supportive CareObinutuzumab InjMedical Oncology & Supportive CareInjection NivolumabSupportive CareMedical Oncology & Supportive CareMedical Oncology & Supportive CareMedical Oncology & Ofatumumab InjectionSupportive CareMedical Oncology & Supportive CareMedical Oncology & Supportive CareOfatumumab InjectionSupportive Care | Medical Oncology & Supportive CareInj. Isatuximab-Irfc 10 MgCarelonMedical Oncology & Supportive CareYervoy_(Ipilimumab)CarelonMedical Oncology & Supportive CareInj Inotuzumab Ozogam 0.1 MgCarelonMedical Oncology & Supportive CarePaclitaxel Protein BoundCarelonMedical Oncology & Supportive CarePegaspargase InjectionCarelonMedical Oncology & Supportive CareInj. Tagraxofusp-Erzs 10 Mcg Supportive CareCarelonMedical Oncology & Supportive CareInj PembrolizumabCarelonMedical Oncology & Supportive CareInj Dostarlimab-Gxly 10 Mg Supportive CareCarelonMedical Oncology & Supportive CareInj Tisotu Vedotin-Tftv 1Mg Supportive CareCarelonMedical Oncology & Supportive CareInj Tebentafusp-Tebn 1 Mcg Supportive CareCarelonMedical Oncology & Supportive CareMitomycin InstillationCarelonMedical Oncology & Supportive CareInj Ection Necitumumab 1 Mg Supportive CareCarelonMedical Oncology & Supportive CareInj Nivol Relatlimab 3Mg/1Mg Supportive CareCarelonMedical Oncology & Supportive CareInjection NivolumabCarelonMedical Oncology & Supportive CareInjection NivolumabCarelonMedical Oncology & Supportive CareInjection NivolumabCarelonMedical Oncology & Supportive CareObinutuzumab InjectionCarelonMedical Oncology & Supportive CareObinutuzumab InjectionCarelon |

| J9308 | Medical Oncology & Inj | jection Ramucirumab | Carelon | Prior Authorization required through |
|-------|------------------------|----------------------------|---------|--------------------------------------|
| | Supportive Care | | | Carelon. |
| J9309 | Medical Oncology & Inj | j Polatuzumab Vedotin 1Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9311 | Medical Oncology & Inj | j Rituximab Hyaluronidase | Carelon | Effective 01/01/2023, Prior |
| | Supportive Care | | | Authorization required through |
| | | | | Carelon. |
| J9313 | Medical Oncology & Inj | j. Lumoxiti 0.01 Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9316 | Medical Oncology & Pe | ertuzu Trastuzu 10 Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9317 | Medical Oncology & Sa | acituzumab Govitecan-Hziy | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9325 | Medical Oncology & Inj | j Talimogene Laherparepvec | Carelon | Effective 01/01/2023, Prior |
| | Supportive Care | | | Authorization required through |
| | | | | Carelon. |
| J9331 | Medical Oncology & Inj | j Sirolimus Prot Part 1 Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9345 | Medical Oncology & Inj | j, Retifanlimab-Dlwr, 1 Mg | Carelon | Add Effective 01/01/2024. Prior |
| | Supportive Care | | | Authorization required through |
| | | | | Carelon. |
| J9347 | Medical Oncology & Inj | j Tremelimumab-Actl 1 Mg | Carelon | Add Effective 7/1/2023; Prior |
| | Supportive Care | | | Authorization required through |
| | | | | Carelon. |
| J9348 | Medical Oncology & Inj | j. Naxitamab-Gqgk 1 Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9349 | Medical Oncology & Inj | j. Tafasitamab-Cxix | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9350 | Medical Oncology & Inj | j Mosunetuzumab-Axgb 1 | Carelon | Add Effective 01/01/2024. Prior |
| | Supportive Care M | lg | | Authorization required through |
| | | | | Carelon. |
| J9352 | Medical Oncology & Inj | jection Trabectedin 0.1Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9353 | Medical Oncology & Inj | j. Margetuximab-Cmkb 5 | Carelon | Prior Authorization required through |
| | Supportive Care M | lg | | Carelon. |
| J9354 | Medical Oncology & Inj | j Ado-Trastuzumab Emt | Carelon | Prior Authorization required through |
| | Supportive Care 1N | Иg | | Carelon. |
| J9355 | Medical Oncology & Inj | j Trastuzumab Excl Biosimi | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9356 | Medical Oncology & Inj | j. Herceptin Hylecta 10Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9358 | Medical Oncology & Inj | j Fam-Trastu Deru-Nxki 1Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |
| J9359 | Medical Oncology & Inj | j Lon Tesirin-Lpyl 0.075Mg | Carelon | Prior Authorization required through |
| | Supportive Care | | | Carelon. |

| J9380 | Medical Oncology & Supportive Care | Inj Teclistamab Cqyv 0.5 Mg | Carelon | Add Effective 7/1/2023; Prior Authorization required through Carelon. |
|-------|---------------------------------------|--|---------|---|
| 19999 | Medical Oncology & Supportive Care | Unituxin (Dinutuximab) | Carelon | Code represents unclassified drugs or biologics. Effective 01/01/2023, add new drug Unituxin (dinutuximab) and Alymsys (bevacizumab-maly); Prior Authorization required through Carelon. |
| Q2043 | Medical Oncology & Supportive Care | Provenge_(Sipuleucel-T) | Carelon | Prior Authorization required through Carelon. |
| Q2050 | Medical Oncology & Supportive Care | Doxil/Lipodox_(Doxorubicin Liposomal) | Carelon | Prior Authorization required through Carelon. |
| Q4081 | Medical Oncology & Supportive Care | Epoetin Alfa 100 Units Esrd | Carelon | Prior Authorization required through Carelon. |
| Q5101 | Medical Oncology & Supportive Care | Injection Zarxio | Carelon | Prior Authorization required through Carelon. |
| Q5105 | Medical Oncology & Supportive Care | Inj Retacrit Esrd On Dialysi | Carelon | Prior Authorization required through Carelon. |
| Q5106 | Medical Oncology & Supportive Care | Inj Retacrit Non-Esrd Use | Carelon | Prior Authorization required through Carelon. |
| Q5107 | Medical Oncology & Supportive Care | Inj Mvasi 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5108 | Medical Oncology & Supportive Care | Injection Fulphila | Carelon | Prior Authorization required through Carelon. |
| Q5110 | Medical Oncology & Supportive Care | Nivestym | Carelon | Prior Authorization required through Carelon. |
| Q5111 | Medical Oncology & Supportive Care | Injection Udenyca 0.5 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5112 | | Inj Ontruzant 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5113 | Medical Oncology & Supportive Care | Inj Herzuma 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5114 | Medical Oncology & Supportive Care | Inj Ogivri 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5115 | Medical Oncology & Supportive Care | Inj Truxima 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5116 | Medical Oncology & Supportive Care | Inj. Trazimera 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5117 | Medical Oncology & Supportive Care | Inj. Kanjinti 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5118 | Medical Oncology & Supportive Care | Inj. Zirabev 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5119 | Medical Oncology & Supportive Care | Inj Ruxience 10 Mg | Carelon | Prior Authorization required through Carelon. |

| Q5120 | Medical Oncology & Supportive Care | Inj Pegfilgrastim-Bmez 0.5Mg | Carelon | Prior Authorization required through Carelon. |
|-------|--|--|----------------------|--|
| Q5122 | Medical Oncology & Supportive Care | Inj Nyvepria | Carelon | Prior Authorization required through Carelon. |
| Q5123 | Medical Oncology & Supportive Care | Inj. Riabni 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5125 | Medical Oncology & Supportive Care | Inj Releuko 1 Mcg | Carelon | Add effective 04/01/2023. Prior Authorization required through Carelon. |
| Q5126 | Medical Oncology & Supportive Care | Inj Alymsys 10 Mg | Carelon | Add Effective 4/1/2023 to replace C9142. Prior Authorization required through Carelon. |
| Q5127 | Medical Oncology & Supportive Care | Inj Stimufend 0.5 Mg | Carelon | Add Effective 7/1/2023; Prior Authorization required through Carelon. |
| Q5129 | Medical Oncology & Supportive Care | Inj Vegzelma 10 Mg | Carelon | Add Effective 7/1/2023; Prior Authorization required through Carelon. |
| Q5130 | Medical Oncology & Supportive Care | Inj Fylnetra 0.5 Mg | Carelon | Add Effective 7/1/2023; Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J0881 | Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Darbepoetin Alfa Non-Esrd | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J0885 | Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Epoetin Alfa Non-Esrd | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1599 | Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection, Immune Globulin, Intravenous, Nonlyophilized (E.G., Liquid), Not Otherwise Specified, 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |

| J9035 | Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Bevacizumab Injection | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
|-------|--|------------------------------|----------------------|--|
| J9312 | Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Inj. Rituximab 10 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| 90283 | Provider Administered Drug Therapy | Human Ig Iv | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| 90284 | Provider Administered Drug Therapy | Human Ig Sc | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| 90378 | Provider Administered Drug Therapy | Rsv Mab Im 50Mg | BCBSNM | Prior Authorization required through BCBS. |
| C9257 | Provider Administered Drug Therapy | Bevacizumab Injection | BCBSNM | Prior Authorization required through BCBS. |
| J0202 | Provider Administered Drug Therapy | Injection Alemtuzumab | BCBSNM | Prior Authorization required through BCBS. |
| J0565 | Provider Administered Drug Therapy | Inj Bezlotoxumab 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0567 | Provider Administered Drug Therapy | Inj. Cerliponase Alfa 1 Mg | BCBSNM | Prior Authorization required through BCBS. Add to Large Groups 10/01/2023. |
| J0585 | Provider Administered Drug Therapy | Injection Onabotulinumtoxina | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J0586 | Provider Administered Drug Therapy | Abobotulinumtoxina | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J0587 | Provider Administered Drug Therapy | Inj Rimabotulinumtoxinb | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| J0588 | Provider Administered Drug Therapy | Xeomin (Incobotulinumtoxina) | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |

| J0775 | Provider | Collagenase Clost Hist Inj | BCBSNM | Prior Authorization required through |
|-------|-------------------|------------------------------|--------|--------------------------------------|
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J0888 | Provider | Epoetin Beta Non Esrd | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J1325 | Provider | Epoprostenol Injection | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J1411 | Provider | Inj Hemgenix Per Tx Dose | BCBSNM | Add effective 01/01/2024 |
| | Administered Drug | | | |
| | Therapy | | | |
| J1428 | Provider | Inj Eteplirsen 10 Mg | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J1562 | Provider | Vivaglobin Inj | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J1675 | Provider | Histrelin Acetate | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J1950 | Provider | Leuprolide Acetate /3.75 Mg | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J2278 | Provider | Ziconotide Injection | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J2326 | Provider | Inj Nusinersen 0.1Mg | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J2502 | Provider | Inj Pasireotide Long Acting | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J2562 | Provider | Plerixafor Injection | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J2941 | Provider | Somatropin Injection | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J3121 | Provider | Inj Testostero Enanthate 1Mg | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J3145 | Provider | Testosterone Undecanoate | BCBSNM | Prior Authorization required through |
| | Administered Drug | 1Mg | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |

| J3285 | Provider | Treprostinil Injection | BCBSNM | Prior Authorization required through |
|-------|-------------------|------------------------------|--------|--------------------------------------|
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J3315 | Provider | Triptorelin Pamoate | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J3398 | Provider | Inj Luxturna 1 Billion Vec G | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J3399 | Provider | Inj Onase Abepar-Xioi Treat | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J7178 | Provider | Inj Human Fibrinogen Con Nos | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. |
| | Therapy | | | |
| J7340 | Provider | Carbidopa Levodopa Ent | BCBSNM | Prior Authorization required through |
| | Administered Drug | 100MI | | BCBS. |
| | Therapy | | | |
| J9029 | Provider | Inj Adstiladrin Per Tx Dos | BCBSNM | Add effective 01/01/2024 |
| | Administered Drug | | | |
| | Therapy | | | |
| J9155 | Provider | Degarelix Injection | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J9202 | Provider | Goserelin Acetate Implant | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J9217 | Provider | Leuprolide Acetate Suspnsion | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J9218 | Provider | Leuprolide Acetate Injeciton | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J9219 | Provider | Leuprolide Acetate Implant | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |
| J9225 | Provider | Vantas Implant | BCBSNM | Prior Authorization required through |
| | Administered Drug | | | BCBS. Add to Small Groups/Mid- |
| | Therapy | | | Markets 10/01/2023. |

| J9226 | Provider Administered Drug Therapy | Supprelin La Implant | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
|-------|--|---|--------|---|
| Q2041 | Provider Administered Drug Therapy | Axicabtagene Ciloleucel Car+ | BCBSNM | Prior Authorization required through BCBS. |
| Q2042 | Provider Administered Drug Therapy | Tisagenlecleucel Car-Pos T | BCBSNM | Prior Authorization required through BCBS. |
| Q2053 | Provider Administered Drug Therapy | Brexucabtagene Car Pos T | BCBSNM | Prior Authorization required through BCBS. |
| Q2054 | Provider Administered Drug Therapy | Lisocabtagene Mara Car Pos T | BCBSNM | Prior Authorization required through BCBS. |
| Q2055 | Provider Administered Drug Therapy | Idecabtagene Vicleucel Car | BCBSNM | Prior Authorization required through BCBS. |
| Q2056 | Provider Administered Drug Therapy | Ciltacabtagene Car-Pos T | BCBSNM | Add effective 01/01/2023 |
| S0157 | Provider Administered Drug Therapy | Becaplermin Gel 1% 0.5 Gm | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |
| S0189 | Provider Administered Drug Therapy | Testosterone Pellet 75 Mg **Trademarks are the property of th | BCBSNM | Prior Authorization required through BCBS. Add to Small Groups/Mid- Markets 10/01/2023. |

ribility and benefits and/or the fact that a service has been preauthorized is not a guarantee of navment. Benefits w

Please note that checking eligibility and benefits and/or the fact that a service has been preauthorized is not a guarantee of payment. Benefits will be determined once a claim is received and will be based upon, among other things, the member's eligibility and the terms of the member's certificate of coverage applicable on the date services were rendered. If you have questions, contact the number on the member's ID card.

Availity is a trademark of Availity, LLC, a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSNM. BCBSNM makes no endorsement, representations or warranties regarding any products or services offered by third party vendors such as Availity. If you have any questions about the products or services offered by such vendors, you should contact the vendor(s) directly

BCBSNM, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association.

Blue Cross and Blue Shield of New Mexico, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association